Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 20,225 shares of the company’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $39.99, for a total value of $808,797.75. Following the sale, the insider owned 246,426 shares of the company’s stock, valued at approximately $9,854,575.74. This represents a 7.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The stock was sold at an average price of $35.08, for a total value of $357,816.00.
• On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.97, for a total value of $320,500.05.
• On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.98, for a total value of $17,490.00.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.90, for a total value of $12,564.00.

Rapport Therapeutics Stock Down 0.5%

Rapport Therapeutics stock opened at $36.78 on Thursday. The business has a fifty day moving average of $30.88 and a two-hundred day moving average of $28.74. The firm has a market cap of $1.76 billion, a P/E ratio of -12.86 and a beta of 1.09. Rapport Therapeutics, Inc. has a twelve month low of $7.73 and a twelve month high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). Equities analysts expect that Rapport Therapeutics, Inc. will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On Rapport Therapeutics

Several hedge funds have recently made changes to their positions in RAPP. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after acquiring an additional 4,582 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC acquired a new position in shares of Rapport Therapeutics in the 1st quarter valued at $2,039,000. Rhumbline Advisers increased its position in shares of Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock valued at $144,000 after acquiring an additional 4,109 shares during the period. Geode Capital Management LLC increased its position in shares of Rapport Therapeutics by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock valued at $3,789,000 after acquiring an additional 17,496 shares during the period. Finally, Creative Planning acquired a new position in shares of Rapport Therapeutics in the 2nd quarter valued at $121,000.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. BTIG Research upped their price target on Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Truist Financial raised Rapport Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research report on Monday, March 9th. Finally, Raymond James Financial assumed coverage on Rapport Therapeutics in a research report on Friday, April 10th. They set a “strong-buy” rating and a $66.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $53.83.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.